Efficacy of Tibolone Versus Transdermal E2/NETA on Sexual Function in Naturally Postmenopausal Women (P06089)

Inclusion Criteria: * Physically and mentally healthy postmenopausal women, \>=48 and \<=68 years of age, with an intact uterus. * Women were to suffer from decreased satisfactory sexual activity compared to younger age and sexual problems were not to be considered caused by relationship/partner problems. The decreased sexual functioning was to result in sexually related personal distress as confirmed by the FSDS (score =15). * An affirmative answer was to be given to the following questions: (a) In previous years did you find sexual activity satisfying? (b) Has there been a decline in your satisfaction with sexual activity? (c) Are you satisfied with your partner as a friend? * All subjects were to have an established sexual relationship of at least 6 months duration prior to screening. * Women were to be sexually active. * Normal mammography within 6 months prior to randomization. * Body mass index \>18 and \<=32 kg/m2. * Voluntary written informed consent Exclusion Criteria: * Any unexplained abnormal uterine bleeding * Double layer endometrial thickness \>4 mm * Tibolone or transdermal E2/NETA use within 3 months prior to screening * Progestogen implants or injections and estrogen/progestogen injectable therapy within 6 months prior to screening * Use of intra-uterine progestogen * Unsuccessful previous treatment with androgens or compounds known to enhance androgenic activity * Current successful treatment with androgens, without applying the applicable washout period of 3 months prior to screening * Any previous or current unopposed estrogen administration, prior use of estrogen pellets or tamoxifen citrate (previous low dose vaginal estrogen-only applications are allowed) * Use of anti -androgens within the preceding 5 years prior to screening. * Women with significant organic disorder of sexual dysfunction or a partner with sexual dysfunction * Women who had early onset sexual dysfunction (\>15 years prior to menopause) * Women suffering from androgenic alopecia, acne or hirsutism * Women suffering from illnesses influencing sexuality * Women using medication influencing sexuality * Moderate to severe depression * Current or prior use of antidepressant within 8 weeks prior to screening * Major gynecological surgery in the preceding 3 months * Any serious disease or disorder; or any endocrine disorder with systemic disease which would have impaired overall health and well being (controlled hypo/hyperthyroidism and diabetes mellitus Type II was allowed) * History or presence of severe psychiatric illness and/or any addictions to drugs, medication or alcohol in the past 3 years * Diseases for which exogenous hormonal steroids were contraindicated. * History or presence of any malignancy, except successfully treated non-melanoma skin cancers * History or presence of cardiovascular or cerebrovascular conditions, thrombosis or thromboembolic disorders * History or presence of liver, gallbladder or renal disease, epilepsy or classical migraine headaches * Uncontrolled hypertension * Women with abnormal cervical smear results * History or presence of breast cancer, suspicious breast lump or mammographic abnormality * Known hypersensitivity to any of the ingredients of the trial medication. * Non-compliance with the screening diary * Current use of raloxifene, clonidine, veralipride, phytoestrogen extracts * Drugs known to interfere with the pharmacokinetics of the steroids * Use of investigational drugs within the past 60 days * Any disease or condition that was clinically relevant and which, in the opinion of the investigator, would have jeopardized the subject's well being during the course of the trial